Product Description
Bemiparin sodium (Hibor, Ivor, Zivor, Badyket, Laboratorios Farmaceuticos Rovi SA) is a new second-generation low molecular weight heparin (LMWH). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12943485/)
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Brazil | Bulgaria | Chile | Colombia | Dominican Republic | Estonia | Hong Kong | Hungary | India | Mexico | Pakistan | Philippines | Russia | Spain | Turkey | United Arab Emirates | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: ANGELA PUENTE
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Infertility
Phase 3: COVID-19|Venous Thromboembolism|Venous Thrombosis|Pelvic Cancer|Thrombosis
Phase 2: COVID-19|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BRIF | P4 |
Completed |
Infertility |
2022-07-01 |
|
BEMICOP | P3 |
Unknown status |
COVID-19 |
2021-05-31 |
|
2020-001548-24 | P2 |
Active, not recruiting |
COVID-19 |
2020-11-28 |
|
BEMI 2015 | P3 |
Completed |
Thrombosis |
2019-02-01 |